COVID-19 vaccine trials from the University of Oxford and Wuhan both show early positive results

BELO HORIZONTE, BRAZIL - MARCH 24: Detail of the standardization of a rapid test for the diagnosis of the disease COVID-19 on March 24, 2020 in Belo Horizonte, Brazil. The Ministry of Health convened The Technological Vaccine Center of the Federal University of Minas Gerais laboratory to conduct research on the coronavirus (COVID-19) in order to diagnose, test and develop a vaccine. According to the Ministry of Health, as of Tuesday, March 24, Brazil has 1.891 confirmed cases of the coronavirus (COVID-19) and at least 34 recorded deceases. (Photo by Pedro Vilela/Getty Images)
BELO HORIZONTE, BRAZIL - MARCH 24: Detail of the standardization of a rapid test for the diagnosis of the disease COVID-19 on March 24, 2020 in Belo Horizonte, Brazil. The Ministry of Health convened The Technological Vaccine Center of the Federal University of Minas Gerais laboratory to conduct research on the coronavirus (COVID-19) in order to diagnose, test and develop a vaccine. According to the Ministry of Health, as of Tuesday, March 24, Brazil has 1.891 confirmed cases of the coronavirus (COVID-19) and at least 34 recorded deceases. (Photo by Pedro Vilela/Getty Images)
Darrell Etherington
·2 mins read

There are more promising signs from ongoing efforts to develop a vaccine that's effective in preventing COVID-19: Two early trials, one from the University of Oxford, and one from a group of researchers in Wuhan funded in part by the National Key R&D Programme of China. Both early trials showed efficacy in increasing the presence of antibody responses to SARS-CoV-2, the virus that leads to COVID-19, and also indicated that these prospective vaccines were safe to administer based on available information.

The University of Oxford study is one of the leading vaccine development efforts in the world, and among those that are furthest along in development. The results of their study covered 1,077 participants, all of whom were health adults aged between 18 and 55 with no prior confirmed history of having contracted SARS-CoV-2. That's important because they received double randomized trials of the vaccine candidate, or an existing vaccine for meningitis as a control acting as a placebo. The results showed that across the group, 100 percent of the participants had demonstrated neutralizing antibody responses by the end of the course, which include a booster does.

Additionally, while some participants exhibited side effects, including "pain, feeling feverish, chills, muscle ache, headache and malaise," none of these represented what the researchers consider serious reactions, and these were also mitigated with use of paracetamol (standard painkillers available over the counter). Patient reactions were monitored for 28 days following the administration of the vaccine.

Oxford's team is now ready to move on to its Phase 3 trial, which is a large-scale human trial that is effectively the last major step before it moves on to potential approval, production and distribution. That's a time consuming process, but it does put this development on pace for a remarkably fast research and development process relative to prior vaccines.

Meanwhile the study in China covered health adults 18 or older, and included 603 participants, screened down to 508 who received either the vaccine candidate or a placebo. The participants also showed no adverse reactions, according to the researchers, and they're also now likely to move on to a phase 3 development program.

Earlier this month, Moderna also announced promising early results from its phase 1 trial, but that was limited to just 45 participants between 18 and 55, and indicated some potentially serious side effects that will need to be watched in later, larger trials. These new results, while also early and requiring further development and research, are much more encouraging given the scale of both trials.

It is very early to make too many assumptions about what these early trials indicate, however. For instance, we still don't really know how effective antibodies are in patients that have recovered from having COVID-19 once, so a lot more investigation is required by scientists in better understanding the efficacy of antibodies, and potentially vaccines, over the long term.

More From

  • Clearview AI landed a new facial recognition contract with ICE

    The controversial facial recognition software maker Clearview AI has a new contract with ICE, the most controversial U.S. government agency. Clearview was already known to work with the branch of Homeland Security fiercely criticized for implementing the Trump administration's harsh immigration policies. The new contract makes it clear that relationship is ongoing — and that Clearview isn't just playing a bit part in tech's lucrative scrum for federal contracts.

  • Birmingham-based Help Lightning raises $8 million for its remote training and support tools

    In the four years since Help Lightning first began pitching its services out of its Birmingham, Ala. headquarters, the company has managed to sign up 100 customers including some large Fortune 500 companies like Cox Communications, Siemens, and Boston Scientific. Now, with an additional $8 million in financing from Resolve Growth Partners, the company is hoping to expand its sales and marketing efforts and continue to refine its product. The technology was initially invented by Bart Guthrie, a neurosurgeon at the University of Alabama at Birmingham, who wanted a way to improve telepresence technologies so he could assist with remote surgeries.

  • Sequoia Capital has internal crash courses for its founders -- here's how they work

    No matter what you think of Sequoia Capital, the firm doesn't rest on its laurels. Recently, to create more room between itself and its ever-growing number of competitors, the firm has also begun fine-tuning a curriculum for the founders of both the pre-seed and seed-stage startups it has funded, as well as its Series A and B-stage founders. According to Roelof Botha -- the U.S. head of the venture firm since 2017 -- and Jess Lee, a partner at Sequoia for nearly four years, the idea is to arm the individuals it backs with Sequoia's vast "tribal knowledge" so they can not only compete with their rivals but, hopefully, outperform them.

  • Facebook pushes back against Apple's App Store fees

    Facebook joined the growing ranks of companies publicly complaining about the 30% fee that Apple collects on payments made through its App Store. Facebook said that to support struggling businesses, it won't be collecting any fees on those events, at least for the next year, which means that those businesses keep 100% of payments on the web and on Android.